Indication
Prevention of cytomegalovirus (CMV) disease in CMV-seronegative recipients of kidney, heart or kidney-pancreas transplant from a CMV-seropositive donor (D+/R−), and other indications per the approved Indian product label.
Mechanism of action
Valganciclovir is the L-valyl ester pro-drug of ganciclovir. After absorption it is rapidly hydrolysed to ganciclovir, which is phosphorylated by viral kinases to ganciclovir triphosphate. This metabolite competitively inhibits viral DNA polymerase and terminates viral DNA elongation.
Strengths
- •450 mg tablet
Composition
Each Valcurb® tablet contains Valganciclovir (as Valganciclovir Hydrochloride) 450 mg.
Presentation
Refer to approved product label / pack insert.
For Healthcare Professionals
Renal-dose adjust by creatinine clearance. Monitor full blood counts weekly during the first month and then per protocol - myelosuppression is the principal class toxicity.
This section is intended for use by registered medical practitioners only. All clinical decisions remain the prescriber's responsibility and should be informed by the current approved product label.
Notes for patients & caregivers
Take with food to improve absorption. Do not break or crush the tablet. Tell your team if you notice unusual bruising, sore throat or fever.
These notes are for general awareness only and are not a substitute for medical advice. Please follow your treating physician's instructions and the directions on the dispensed product.
Storage
Store below 30°C. Protect from moisture.
Important
- • Valcurb® is a prescription medicine. It must only be used on the advice of a registered medical practitioner.
- • Always refer to the current approved Indian product label / package insert for definitive prescribing information.
- • If you experience any quality or safety concern, please contact us or write to info@vyapitus.com.